| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/18/2004 | US20040053899 Method of preparing a pharmaceutical composition |
| 03/18/2004 | US20040053898 For organ specific therapy; for treatment of menopausal symptoms, hormone-deficiency diseases and neurodegenerative diseases |
| 03/18/2004 | US20040053897 Selective androgen receptor modulators (SARMs); for inhibition of mitogenic action of testosterone and dihydrotestosterone; also for treatment of hair loss |
| 03/18/2004 | US20040053896 Pharmaceutically active compound |
| 03/18/2004 | US20040053895 Plastic blow fill containers; for parenteral administration; needleless |
| 03/18/2004 | US20040053894 Improved water solubility; drug delivery; avoids irritation |
| 03/18/2004 | US20040053892 Chiral integrin modulators and methods of use thereof |
| 03/18/2004 | US20040053890 Naphthalene derivatives |
| 03/18/2004 | US20040053889 Such as 2-(5-chlorothiophen-2-yl)-4,4,5,5-tetramethyl-(1,3,2) dioxaborolane for inhibition of hormone-sensitive lipase against triacylglycerols; for modulating levels of high/low density lipoproteins |
| 03/18/2004 | US20040053888 Cyclodextrin-containing pharmaceutical preparation |
| 03/18/2004 | US20040053885 Use of hyaluronic acid derivatives for the prevention of inflammatory arthritis |
| 03/18/2004 | US20040053884 Comprises N-acylated hydroxyproline derivatives and glycosaminoglycans (chondroitin sulfate); for treatment of arthritis |
| 03/18/2004 | US20040053883 Crystalline forms of pyrimidine nucleoside derivative |
| 03/18/2004 | US20040053882 Comprises sterically hindered platinum coordination compound such as (SP-4-3)-(cis-aminedichloro-(2-methylpyridine)platinum complex, non- platinum based anticancer agent (taxol), and carrier; kits |
| 03/18/2004 | US20040053881 Adenosine derivatives and use thereof |
| 03/18/2004 | US20040053875 Comprises double-stranded RNA; extracted from HeLa cells |
| 03/18/2004 | US20040053874 Polynucleotide that hybridize with and inhibit gene expression for amphipathic dimeric glycoproteins |
| 03/18/2004 | US20040053872 Administering polynucletides that inhibit interactions polymerases with tRNA, to humans for prophylaxis of aquired immune deficiency syndrome |
| 03/18/2004 | US20040053869 Stem cell differentiation |
| 03/18/2004 | US20040053864 Prophylaxis and diagnosis of bone disorders such as osteoporosis or paget's disease, by controlling signal transduction, biosynthesis or receptor binding of polypeptide hormones |
| 03/18/2004 | US20040053863 Sensitization of HER-2/neu overexpressing cancer cells to chemotherapy |
| 03/18/2004 | US20040053862 Macrolide solvates |
| 03/18/2004 | US20040053860 Flavonoid derivatives for the treatment of eczema |
| 03/18/2004 | US20040053858 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
| 03/18/2004 | US20040053857 Glycoalkaloid compositions and various uses thereof |
| 03/18/2004 | US20040053856 Method of producing a tampon capable of inhibiting exoprotein production from gram positive bacteria |
| 03/18/2004 | US20040053855 Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
| 03/18/2004 | US20040053854 Process for preparation of 4,5-Epoxymorphinan-6-oxyglucuronides |
| 03/18/2004 | US20040053853 Topiramate salts and compositions comprising and methods of making and using the same |
| 03/18/2004 | US20040053852 Preventing desensitization of receptors |
| 03/18/2004 | US20040053851 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 03/18/2004 | US20040053850 Treatment of demyelinating diseases |
| 03/18/2004 | US20040053844 Peptide and osteogenetic accelerator |
| 03/18/2004 | US20040053842 Cholesterol ester transfer protein inhibitors for use in treating atherosclerosis optionally in combination with other antihypertensive agents |
| 03/18/2004 | US20040053833 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds |
| 03/18/2004 | US20040053832 Prevention of Ca2+-influx and reduction of cAMP/cGMP-ratio in immune effector cells by use of combination of Ca-antagonist, and an agent able to decrease the intracellular cAMP/cGMP-ratio |
| 03/18/2004 | US20040053826 Uses of polypeptides |
| 03/18/2004 | US20040053815 Inactivating a nuclear localization signal of a protein by contacting the protein with a compound that binds reversibly; parasiticides; viricides |
| 03/18/2004 | US20040053814 Methods of agonizing and antagonizing FabK |
| 03/18/2004 | US20040053813 Method of extending the dose range of vitamin D compounds |
| 03/18/2004 | US20040053379 Method of producing polyunsaturated fatty acids, novel biosynthesis genes, and novel plant expression constructs |
| 03/18/2004 | US20040053316 Contacting composition with an aziridine derivative inactivating agent; killed virus-containing vaccines |
| 03/18/2004 | US20040053289 Comprises oligonucleotide sequences for us as antitumor agents, viricides, fungicides, herbicides and/or pesticides |
| 03/18/2004 | US20040053265 Using differential gene expression of flotillin gene products to diagnose and prognose brain disorders |
| 03/18/2004 | US20040053262 Supressor gene |
| 03/18/2004 | US20040053259 Comprises methylated antisense oligonucleotide sequence for regulation of urokinase type plasminogen activator and treatment of cancer |
| 03/18/2004 | US20040053228 Apoptosis inhibitory polypeptides, gene and polynucleotide encoding it and compositions containing the same |
| 03/18/2004 | US20040053208 Methods to selectively inactivate parasites in biological compositions |
| 03/18/2004 | US20040052922 Nutritional and therapeutical preparations having antioxidant activity |
| 03/18/2004 | US20040052881 Compositions and methods for cancer prevention and treatment derived from Inula britannica |
| 03/18/2004 | US20040052879 Solvent extraction with methanol; isomerization; antitumor agents |
| 03/18/2004 | US20040052877 Comprises ginger perfume as a refrigerant; steam distillation; contact lens |
| 03/18/2004 | US20040052875 Method and perparations having effect against allergic symptoms |
| 03/18/2004 | US20040052874 Synergistic composition for treating leukemia |
| 03/18/2004 | US20040052873 Bioavailability / bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof |
| 03/18/2004 | US20040052871 Health enhancement system |
| 03/18/2004 | US20040052869 Orally ingestible preparation of mistletoe lectins and method |
| 03/18/2004 | US20040052864 Comprises decitabine as methylation inhibitor; kits; tumor suppressor genes/proteins; interleukins; vaccines |
| 03/18/2004 | US20040052863 Comprises vitamin C, vitamin E, vitamin A (beta-carotene), zinc oxide, and cupric oxide; for promotion of retinal health |
| 03/18/2004 | US20040052855 Pouring a dissolved biodegradable polymer and a drug in a low water soluble solvents, a surfactant and homogenizing, filtering, washing and freeze drying |
| 03/18/2004 | US20040052851 Glassy matrix of a hydrophobic sugar alcohol, water soluble gelling gum and an active agent; transmucosal nicotine to reduce cravings |
| 03/18/2004 | US20040052848 Single phase matrix of metformin and a controlled release excipient; maximum serum concentration is 3-12 hours after administration |
| 03/18/2004 | US20040052847 Oral dosage forms of water insoluble drugs and methods of making the same |
| 03/18/2004 | US20040052845 Hydrogel-driven drug dosage form |
| 03/18/2004 | US20040052843 Controlled release dosage forms |
| 03/18/2004 | US20040052842 Delayed and immediate release dosage forms; once a day administration; maximum serum concentration is reached in </=12 hours |
| 03/18/2004 | US20040052841 Pharmaceutical preparation with retarding active ingredient release, method for its production and its use |
| 03/18/2004 | US20040052840 Preparations for oligonucleotide transfer |
| 03/18/2004 | US20040052837 Lipid conjugated anti-cancer drugs and methods of use thereof |
| 03/18/2004 | US20040052835 Matrix controlled transdermal system for stabile derivatives of ace inhibitors |
| 03/18/2004 | US20040052833 Contacting infectious proteins with a salt of an alkyl sulfate (sodium dodecylsulfate) allowing the proteins to remain in contact with alkyl sulfate salt for a specific time and temp. so as to render proteins noninfectious |
| 03/18/2004 | US20040052832 Acid-labile active ingredient is present in the individual active ingredient units in a matrix composed of a mixture of solid praffin, and one or more substances form fatty alcohol, fatty ester and triglyceride |
| 03/18/2004 | US20040052828 Provide a cooling sensation to a consumer, which cooling component includes cyclopenten-1-one-2-enamine derivative |
| 03/18/2004 | US20040052826 Cosmetic and pharmaceutical compositions and their use |
| 03/18/2004 | US20040052823 Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells |
| 03/18/2004 | US20040052795 Wound healing agents, antiscarring agents |
| 03/18/2004 | US20040052787 Screening for menstruation disorders; measurement nucleic acids or protein |
| 03/18/2004 | US20040052785 Synergistic mixtures; antitumor agents |
| 03/18/2004 | US20040052778 Mixture of iodide, thiocyanates, periodic acid and peroxygenase; viricides; killing spores |
| 03/18/2004 | US20040052763 Target antigens; vaccine |
| 03/18/2004 | US20040052761 Sustaine release; drug delivery; injections |
| 03/18/2004 | US20040052757 Dermal abrasion facial peel using sodium bicarbonate |
| 03/18/2004 | US20040052754 Complexes of phosphate derivatives |
| 03/18/2004 | US20040052750 Topical applying; adjust collagen biosynthesis; mixture of phenytoin, valproic acid, cyclosporin, nifedipine, diltazem,verapamil hydrochloride and amoldipine |
| 03/18/2004 | US20040052741 Compositions for the treatment of pigmentation disorders and methods for their manufacture |
| 03/18/2004 | US20040052739 Sunscreen agents; radiation resistance |
| 03/18/2004 | US20040052735 Mixture of oleoresin and spilanthol; food, drugs, cosmetics |
| 03/18/2004 | US20040052734 Process for providing a stable crystalline form of salbutamol |
| 03/18/2004 | US20040052732 Synergistic mixture of antiserotonine agents and glucocorticoids; inhalation |
| 03/18/2004 | US20040052729 Immobilization carbohydrates; calibration; diagnosis; antiinflammatory agents, bactericides |
| 03/18/2004 | US20040050335 Animal feed supplement containing d-pantothenic acid and/or its salts, improved method for the production thereof, and its use |
| 03/18/2004 | DE10261986A1 Hämokompatibel beschichtete Oberflächen Hemocompatibly coated surfaces |
| 03/18/2004 | DE10241670A1 Treating skin diseases, infections or wounds, especially malanders in horses, using preparations containing grapefruit pip extract and homeopathic dilution(s) of (+)-lactic acid with medicinal alcohol |
| 03/18/2004 | DE10241407A1 Behandlung nicht allergischer Rhinitis durch selektive Phosphodiesterase 4-Hemmstoffe Treatment not allergic rhinitis by selective phosphodiesterase 4 inhibitors |
| 03/18/2004 | DE10241395A1 Coffein enthaltende Zusammensetzung als Hautpflegemittel Caffeine-containing composition as a skin care product |
| 03/18/2004 | DE10240735A1 Regulating human endostatin expression, e.g. for treating CNS disorders or tumors, using nitrogen monoxide signal cascade modulators |
| 03/18/2004 | DE10239238A1 Flüssigkonzentrat zur Konservierung von kosmetischen und pharmazeutischen Produkten Liquid concentrate for the preservation of cosmetic and pharmaceutical products |
| 03/18/2004 | DE10238677A1 Mixture for oral ingestion, useful as a medicament, dietetic product or dietary supplement, comprises defined amounts of vitamins, selenium and zinc |
| 03/18/2004 | CA2707068A1 Clear ophthalmic solution comprising latanoprost as active ingredient |
| 03/18/2004 | CA2707067A1 Clear ophthalmic solution comprising latanoprost as active ingredient |